Skip to content

Released Mar 31, 2022, after the close

10-K filed Mar 31, 2022, 90 days after period end · 0000950170-22-005194

Q4 2021 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$29.30MderivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$27,502,000N/M
Operating Cash Flowderived-$27,349,000N/M

What the release said

The release

Same quarter

MetricQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019Q4 2018
Revenue—$0.00$696.00K$1.69M
Net Income-$29.30M-$18.60M-$24.99M-$10.60M
EPS Diluted——-$1.31-$0.60

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR